Ascentage Pharma Reports Promising Study Results at EHA 2025

Ascentage Pharma Group International ( (HK:6855) ) has shared an update.

Ascentage Pharma announced promising results from 13 studies at the 2025 European Hematology Association Congress, highlighting the potential of its novel drug olverembatinib and investigational EED inhibitor APG-5918. Olverembatinib, a third-generation tyrosine kinase inhibitor, showed significant clinical benefits in treating Philadelphia chromosome-positive acute lymphoblastic leukemia, with high remission rates and favorable tolerability. The studies also revealed the drug’s potential in combination therapies, offering more treatment options for patients. APG-5918 demonstrated potent antitumor activity in preclinical studies, supporting its further clinical development.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

More about Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on developing novel therapies for cancer, chronic hepatitis B, and age-related diseases. The company specializes in creating small-molecule therapeutics, with a significant emphasis on innovative drug development targeting apoptosis and autophagy pathways.

Average Trading Volume: 4,494,020

Technical Sentiment Signal: Buy

Current Market Cap: HK$21.54B

See more insights into 6855 stock on TipRanks’ Stock Analysis page.